Company
University whose Orbit AI platform provides AI-powered guidance to entrepreneurs.
Every investor coverage indicates participated in a round MIT raised.
Companies MIT acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Aleksander Madry | Director | SmartCompany |
| Silvio Micali | Professor | @AuManufacturing |
Stories naming MIT. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Startup Daily profiles the thirteen startups joining Startmate's Winter '25 cohort, covering healthcare AI, agent tooling, recruitment tech, retail promotions, sexual health, water leak detection, VR haptics and ADHD robotics.
Feature on Australian capital moving into fusion energy: super fund Hostplus backs Commonwealth Fusion Systems, Foxglove Capital's Matt Bungey backs Type One, and startup HB11 Energy pursues laser proton-boron fusion locally.
Breakthrough Victoria will give applicants to its Fellowship Program access to MIT's Orbit AI, an OpenAI-powered tool that helps researchers test commercial ideas before applying.
Fusion startup Type One Energy has pulled in a $53.5m extension to its seed round, led by Breakthrough Energy Ventures with Foxglove Ventures and GD1 taking part, to accelerate its stellarator reactor plans.
Also Forbes Australia
Birchal's cofounder argues equity crowdfunding is closing the capital gap for founders outside the big cities, citing Western Australia's FY23 growth and two regional companies reaching the $5 million cap.
Two Australian consortia, AROSE and one involving EPE and Lunar Outpost Oceania, each received a four million dollar grant under the Space Agency's Trailblazer programme to design lunar rover prototypes.
Monash University is named among ten international winners of Algorand Foundation grants supporting blockchain research, education and sustainability, including an Algorand Centre of Excellence at the Melbourne university.
Opal Therapeutics partners with Massachusetts General Hospital on an HIV immunotherapy collaboration as human trials begin in London; the biotech counts Alloy Ventures, Alta Partners and GBS Ventures among its backers.